Did you see our feature in this BioSpace article? In this piece, Hong I. Wan, CEO of Tallac Therapeutics, discusses the features of Tallac’s TAC-001, a TLR9 agonist ADC, and how it could potentially benefit a broader patient population with increased safety and tolerability. Read the full article here: https://lnkd.in/gi779jJu https://lnkd.in/gkWcfTXt
With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy. https://hubs.li/Q02FyS5B0